BR112022016784A2 - Anticorpo monoclonal humanizado para o coronavírus 2019 e seu uso - Google Patents

Anticorpo monoclonal humanizado para o coronavírus 2019 e seu uso

Info

Publication number
BR112022016784A2
BR112022016784A2 BR112022016784A BR112022016784A BR112022016784A2 BR 112022016784 A2 BR112022016784 A2 BR 112022016784A2 BR 112022016784 A BR112022016784 A BR 112022016784A BR 112022016784 A BR112022016784 A BR 112022016784A BR 112022016784 A2 BR112022016784 A2 BR 112022016784A2
Authority
BR
Brazil
Prior art keywords
coronavirus
monoclonal antibody
humanized monoclonal
ncov
rbd
Prior art date
Application number
BR112022016784A
Other languages
English (en)
Inventor
Yan Jinghua
Shi Rui
Wang Qihui
Gao Fu
Ma Sufang
Original Assignee
Inst Microbiology Cas
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Inst Microbiology Cas filed Critical Inst Microbiology Cas
Publication of BR112022016784A2 publication Critical patent/BR112022016784A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
    • C07K16/1002—Coronaviridae
    • C07K16/1003—Severe acute respiratory syndrome coronavirus 2 [SARS‐CoV‐2 or Covid-19]
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56983—Viruses
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/577—Immunoassay; Biospecific binding assay; Materials therefor involving monoclonal antibodies binding reaction mechanisms characterised by the use of monoclonal antibodies; monoclonal antibodies per se are classified with their corresponding antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/515—Complete light chain, i.e. VL + CL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/005—Assays involving biological materials from specific organisms or of a specific nature from viruses
    • G01N2333/08—RNA viruses
    • G01N2333/165—Coronaviridae, e.g. avian infectious bronchitis virus
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2469/00—Immunoassays for the detection of microorganisms
    • G01N2469/10—Detection of antigens from microorganism in sample from host

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Virology (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Organic Chemistry (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • General Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Cell Biology (AREA)
  • Pathology (AREA)
  • Microbiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Communicable Diseases (AREA)
  • Animal Behavior & Ethology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Genetics & Genomics (AREA)
  • Oncology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biophysics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pulmonology (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

ANTICORPO MONOCLONAL HUMANIZADO PARA O CORONAVÍRUS 2019 E SEU USO. A presente invenção proporciona um anticorpo monoclonal humanizado para o coronavírus 2019 (2019-nCOV) e o seu uso. O anticorpo é capaz de se ligar especificamente a um domínio de ligação ao receptor (RBD) do 2019-nCOV e bloquear a ligação entre o RBD do 2019-nCOV e a ACE2 e, além disso, inibir a infecção causada pelo 2019-nCOV.
BR112022016784A 2020-02-24 2021-02-23 Anticorpo monoclonal humanizado para o coronavírus 2019 e seu uso BR112022016784A2 (pt)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
CN202010114283 2020-02-24
CN202010137486 2020-03-02
CN202110044541 2021-01-13
PCT/CN2021/077392 WO2021169932A1 (zh) 2020-02-24 2021-02-23 新型冠状病毒的人源单克隆抗体及其应用

Publications (1)

Publication Number Publication Date
BR112022016784A2 true BR112022016784A2 (pt) 2022-11-08

Family

ID=77490247

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112022016784A BR112022016784A2 (pt) 2020-02-24 2021-02-23 Anticorpo monoclonal humanizado para o coronavírus 2019 e seu uso

Country Status (12)

Country Link
US (1) US20230073067A1 (pt)
EP (1) EP4019541A4 (pt)
JP (1) JP2023516147A (pt)
KR (1) KR20230035217A (pt)
CN (1) CN113444169B (pt)
AU (1) AU2021225827A1 (pt)
BR (1) BR112022016784A2 (pt)
CA (1) CA3168749A1 (pt)
IL (1) IL295866A (pt)
MX (1) MX2022010379A (pt)
TW (1) TWI789711B (pt)
WO (1) WO2021169932A1 (pt)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2022261153A1 (en) 2021-06-08 2022-12-15 Eli Lilly And Company 2019 novel coronavirus antibody-containing pharmaceutical formulations
CN113735969B (zh) * 2021-09-20 2023-05-12 中国人民解放军军事科学院军事医学研究院 一种全人源抗新冠病毒广谱高中和活性单克隆抗体及应用
WO2023108936A1 (zh) * 2021-12-14 2023-06-22 杭州安旭生物科技股份有限公司 一种可结合SARS-CoV-2病毒的中和抗体及其应用
CN114044821B (zh) * 2022-01-10 2022-03-25 中国人民解放军军事科学院军事医学研究院 一种抗新冠病毒全人源广谱中和抗体zwc12及应用
CN114560930B (zh) * 2022-04-27 2022-09-23 清华大学 抗新型冠状病毒的广谱中和抗体及其应用
CN114989308B (zh) * 2022-05-12 2023-04-04 中国科学院微生物研究所 新冠病毒嵌合核酸疫苗及其用途

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK2193802T3 (da) * 2005-02-08 2012-06-25 New York Blood Ct Inc Neutraliserende monoklonale antistoffer mod med svært akut respirationssyndrom associeret coronavirus
DK2578685T3 (da) 2005-08-23 2019-06-03 Univ Pennsylvania Rna indeholende modificerede nukleosider og fremgangsmåder til anvendelse deraf
SG10202005268WA (en) * 2015-12-04 2020-07-29 Memorial Sloan Kettering Cancer Center Antibodies targeting fc receptor-like 5 and methods of use
CN108250296B (zh) * 2018-01-17 2020-07-07 长春金赛药业有限责任公司 全人源抗人pd-l1单克隆抗体及其应用
CN110790838B (zh) * 2018-08-02 2023-01-03 广东旋玉健康生物科技有限公司 阻断ev71感染的单克隆抗体及其应用
CN114409769B (zh) * 2019-02-15 2023-05-09 中国科学院微生物研究所 一种裂谷热病毒人源单克隆抗体及其应用

Also Published As

Publication number Publication date
MX2022010379A (es) 2023-01-30
EP4019541A1 (en) 2022-06-29
JP2023516147A (ja) 2023-04-18
WO2021169932A1 (zh) 2021-09-02
US20230073067A1 (en) 2023-03-09
TWI789711B (zh) 2023-01-11
EP4019541A4 (en) 2023-08-09
CN113444169A (zh) 2021-09-28
TW202132349A (zh) 2021-09-01
IL295866A (en) 2022-10-01
CA3168749A1 (en) 2021-09-02
CN113444169B (zh) 2021-12-28
KR20230035217A (ko) 2023-03-13
AU2021225827A1 (en) 2022-09-15

Similar Documents

Publication Publication Date Title
BR112022016784A2 (pt) Anticorpo monoclonal humanizado para o coronavírus 2019 e seu uso
BR112022013545A2 (pt) Anticorpos anti-tigit e método de uso
BR112021011762A2 (pt) Compostos para modulação de fxr (nr1h4)
CR20150054A (es) Anticuerpos anti-cxcr5 humanizados derivados de los mismos y su uso
PE20211412A1 (es) Anticuerpos anti-gdf15, composiciones y metodos de uso
BRPI1013428A2 (pt) anticorpos humanizados para axl
CO2020000214A2 (es) Anticuerpos agonistas que se unen a cd137 humano y sus usos
EA200901119A1 (ru) АНТИТЕЛА ПРОТИВ ErbB3 И ИХ ПРИМЕНЕНИЕ
BR112022014189A2 (pt) Conjugado de anticorpo anti-trop-2 análogo de exatecano e uso médico do mesmo
BRPI0809665B8 (pt) anticorpo monoclonal que se liga especificamente a endosialina
CO6630180A2 (es) Composiciones y métodos de uso terapéutico para anticuerpos multivalentes de lrp6 ( proteínas relacionada con lipoproteinas de baja densidad
EA201991769A1 (ru) ФАРМАЦЕВТИЧЕСКАЯ КОМПОЗИЦИЯ С НИЗКИМ ПОКАЗАТЕЛЕМ pH, СОДЕРЖАЩАЯ КОНСТРУКЦИИ НА ОСНОВЕ АНТИТЕЛА, ОСУЩЕСТВЛЯЮЩИЕ РЕКРУТИНГ Т-КЛЕТОК
CO2023000055A2 (es) Moléculas agonistas de unión al antígeno cd28 que se dirigen a her2
MX2021010893A (es) Anticuerpo biespecifico enlazado especificamente a vegf y ang2.
EA202191890A1 (ru) Ингибиторы pcsk9 и способы их применения
BR112022013403A2 (pt) Anticorpos anti-tigit, anticorpos multiespecíficos que compreendem os mesmos e métodos de uso dos mesmos
BR112022003282A2 (pt) Glicovariantes de igm
BR112022013298A2 (pt) Anticorpos anti-tigit, anticorpos multiespecíficos que compreendem os mesmos e métodos de uso dos mesmos
BR112021016955A2 (pt) Composição, composição de ácido nucleico, composição de vetor de expressão, vetor de expressão, célula hospedeira, métodos de produção de um domínio de ligação de membro de família 3 de pirofosfatase/fosfodiesterase de ectonucleotídeo e de tratamento de um câncer, anticorpo anti-enpp3, e, anticorpo heterodimérico
BR112021023540A2 (pt) Agentes de afinidade
CL2022000438A1 (es) Anticuerpos anti-tgf-beta 1 latente y métodos de uso
BR112022012093A2 (pt) Anticorpos contra integrina alfa 11 beta 1
BR112015021964A2 (pt) Anticorpo isolado ou um fragmento ligante de antígenos do mesmo que se liga especificamente a cxcl13, composição e seus usos
BR112022001985A2 (pt) Métodos para tratamento de câncer pelo uso de inibidores do eixo pd-1 e anticorpos anti-periostina
CY1120737T1 (el) Αντιμικροβιακη τσιμεντοειδης συνθεση, μεθοδος και αντικειμενο